Construction method of eye disease animal model and application of construction method

A disease and eye disease technology, applied to medical preparations containing active ingredients, pharmaceutical formulas, compound screening/testing, etc., can solve problems such as high cost and unsuitable for large-scale use

Active Publication Date: 2019-07-19
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF15 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, although medium and large animals have large eyeballs, they are not suitable for large-scale use due to their high cost. This has become a drawback that cannot be ignored in the above models.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Construction method of eye disease animal model and application of construction method
  • Construction method of eye disease animal model and application of construction method
  • Construction method of eye disease animal model and application of construction method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] Example 1 Overexpression of VEGFR in the eyes of experimental mice

[0130] Rats were injected with VEGFR overexpressing adenovirus (3.5×10 7 After 3 days, the iris tissues of the experimental mice were randomly extracted from the normal control group, the ADV-VEGFR group and the ADV-blank vector group, and Western blot experiments were performed to analyze the differences in protein expression.

[0131] see results figure 1 . figure 1 The protein expression and statistical results of VEGFR in the tissue samples of the present invention are shown. The expression of VEGFR in the ADV-VEGFR group is significantly up-regulated compared with the ADV-blank vector group (P0.05).

Embodiment 2

[0132] Example 2 Analysis of Intraocular Pressure Monitoring Results

[0133] After verifying the overexpression of VEGFR, inject VEGF microsomes (50ng / μl, the total drug loading capacity of microsomes is 10μg, and the diameter is 150nm) in the anterior chamber, and use blank microsomes to exclude the influence of nanoparticles on the outflow of aqueous humor. The intraocular pressure of rats in each group was monitored at the same time period every day with a tonometer, and the intraocular pressure results were statistically analyzed.

[0134] see results figure 2 . figure 2 It shows that on the 7th day after modeling, the intraocular pressure of rats in the VEGF particle group began to increase (14.97±0.9207mmHg), and on the 14th day the intraocular pressure was significantly higher than that of the blank particle group (24.23±0.9333mmHg), and the intraocular pressure dropped to normal on the 21st day level (9.533±0.4055mmHg); the intraocular pressure of the rats did not...

Embodiment 3

[0135] Embodiment 3 Anterior segment photographic result analysis

[0136] On the 1st, 2nd, 4th, 7th, 14th, and 21st days after modeling, the changes of the anterior segment were observed with slit lamp, and the rats were anesthetized by intraperitoneal injection of 10% chloral hydrate. Flashes or bloody aqueous humor, color changes in iris tissue, new blood vessels visible under the microscope in iris tissue, changes in pupil shape.

[0137] see results image 3 . image 3 It showed that the anterior segment of the experimental mice did not have side effects such as corneal edema, corneal deposits, and aqueous humor flashes after modeling.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides a construction method of an eye disease animal model and an application of the construction method. Specifically, the invention provides a model making reagent. The model makingreagent comprises (a) a VEGF sustained release preparation and (b) VEGFR or an expression vector thereof. The (a)VEGF sustained release preparation and the(b) VEGFR or the expression vector thereof are combined for use, so that the eye disease animal model can be effectively constructed.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular, the invention relates to a method for constructing an animal model of an eye disease and its application. Background technique [0002] The formation of new blood vessels in the eye is one of the causes of clinical blindness in ophthalmology, and it is mainly related to vascular diseases that cause intraocular ischemia and hypoxia. There are many diseases that cause neovascularization, and clinically common ones include diabetes, retinal artery occlusion, and ischemic central retinal vein occlusion. Neovascularization may occur in many tissues of the eye, such as corneal neovascularization, iris neovascularization, choroidal neovascularization, ciliary body neovascularization, and retinal neovascularization. Therefore, studying the key molecules that affect its production, or finding new drugs that interfere with its progress, will have a major impact on the clinical progress of ophth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/18A61K49/00
CPCA61K38/1866A61K49/0008
Inventor 刘堃蒋炎郑颖王婧
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap